ResAPP results and scientific transparency, page-5

Well put. Given that so much sits on the accurate determination of the product's ability to correctly detect disease it seems very odd that more of a deal has not been made of the lack of clarity about the results. Calculating the sensitivity and specificity from trail results needs to be done with caution (true) but is -- in my understanding -- pretty much bread-and-butter work for a statistician. If so, why the secrecy? Why not be open and honest (like RAP management used to be) with shareholders. Something is off...